Investment analysts at HC Wainwright assumed coverage on shares of Amicus Therapeutics (NASDAQ:FOLD) in a research report issued to clients and investors on Monday, June 17th, MarketBeat reports. The brokerage set a “buy” rating and a $18.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 46.94% from the stock’s previous close.
Several other equities analysts have also issued reports on the company. Cantor Fitzgerald set a $20.00 price target on Amicus Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, May 8th. Robert W. Baird set a $20.00 price target on Amicus Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 22nd. Janney Montgomery Scott started coverage on Amicus Therapeutics in a research report on Friday, April 5th. They issued a “buy” rating and a $13.91 target price for the company. ValuEngine raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Finally, BidaskClub raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 25th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $18.06.
Shares of Amicus Therapeutics stock traded down $0.20 on Monday, hitting $12.25. The stock had a trading volume of 1,873,075 shares, compared to its average volume of 3,074,791. The firm has a market cap of $2.82 billion, a PE ratio of -9.21 and a beta of 1.77. The firm has a 50-day moving average of $11.98. Amicus Therapeutics has a one year low of $8.27 and a one year high of $16.82. The company has a debt-to-equity ratio of 0.45, a quick ratio of 7.21 and a current ratio of 7.33.
In other news, CEO John F. Crowley sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $12.47, for a total transaction of $249,400.00. Following the sale, the chief executive officer now directly owns 770,194 shares of the company’s stock, valued at approximately $9,604,319.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael Raab sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $11.16, for a total value of $55,800.00. Following the sale, the director now directly owns 13,895 shares in the company, valued at $155,068.20. The disclosure for this sale can be found here. Insiders sold a total of 115,000 shares of company stock valued at $1,508,400 over the last 90 days. 2.90% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the business. Sphera Funds Management LTD. grew its position in shares of Amicus Therapeutics by 1.6% during the 1st quarter. Sphera Funds Management LTD. now owns 2,488,078 shares of the biopharmaceutical company’s stock worth $33,838,000 after buying an additional 40,084 shares in the last quarter. First Trust Advisors LP bought a new stake in Amicus Therapeutics during the first quarter valued at about $635,000. Redmile Group LLC boosted its position in Amicus Therapeutics by 135.7% during the first quarter. Redmile Group LLC now owns 19,616,062 shares of the biopharmaceutical company’s stock valued at $266,778,000 after purchasing an additional 11,292,845 shares in the last quarter. Marshall Wace North America L.P. boosted its position in Amicus Therapeutics by 20.9% during the first quarter. Marshall Wace North America L.P. now owns 6,430,019 shares of the biopharmaceutical company’s stock valued at $87,448,000 after purchasing an additional 1,113,735 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in Amicus Therapeutics by 6.9% during the first quarter. Marshall Wace LLP now owns 169,001 shares of the biopharmaceutical company’s stock valued at $2,299,000 after purchasing an additional 10,911 shares in the last quarter.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.